News
Liverpool are on the verge of signing Eintracht Frankfurt centre-forward Hugo Ekitiké (23) in a €90m deal. L'Equipe has ...
There are all these drugs available, sitting in your local pharmacy, but they aren’t being used to treat all the conditions ...
There’s a certain kind of silence that falls on a room the moment you mention network marketing in Uganda. It’s the kind of ...
1h
News-Medical.Net on MSNLiver identified as key driver of cancer cachexiaMany people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body.
Research by Takebe et al. demonstrated that vascularised liver organoids derived from induced pluripotent stem cells (iPSCs) ...
Obesity, a complex health issue, isn't solely due to inactivity, a study in PNAS reveals. Researchers found similar calorie ...
Discover a study validating the TRIUMPH machine learning model, which improves prediction of post-transplant recurrence in ...
Singaporean researchers have unveiled a new artificial intelligence-based scoring tool designed to predict the recurrence of ...
Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, ...
Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early ...
GlobalData on MSN12h
Sarepta refuses to pull gene therapy despite FDA orderSarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.
This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results